SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

[1]  Deepak L. Bhatt,et al.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[2]  R. Gilbert,et al.  Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials , 2019, Diabetes, obesity & metabolism.

[3]  B. Zinman,et al.  Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. , 2019, Kidney international.

[4]  H. Nagasu,et al.  Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging. , 2019, Circulation.

[5]  B. Akıncı.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. , 2019, The New England journal of medicine.

[6]  M. Jardine,et al.  Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis , 2019, Diabetes, obesity & metabolism.

[7]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[8]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[9]  H. Heerspink.  Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[11]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[12]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[13]  M. Landray,et al.  The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study , 2018, Clinical kidney journal.

[14]  B. Zinman,et al.  Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. , 2018, Journal of the American Society of Nephrology : JASN.

[15]  K. Mahaffey,et al.  Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function , 2018, Circulation.

[16]  K. Mahaffey,et al.  Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. , 2018, The lancet. Diabetes & endocrinology.

[17]  J. Buse,et al.  Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study , 2018, Diabetes, obesity & metabolism.

[18]  H. Heerspink,et al.  Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. , 2018, Kidney international.

[19]  D. Bell,et al.  Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk , 2018, Diabetes Therapy.

[20]  B. Zinman,et al.  Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease , 2018, Circulation.

[21]  V. Perkovic,et al.  Are SGLT2 Inhibitors Ready for Prime Time for CKD? , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[22]  K. Tuttle,et al.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[23]  B. Zinman,et al.  Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[24]  Vlado Perkovic,et al.  Chronic kidney disease and the global NCDs agenda , 2017, BMJ Global Health.

[25]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[26]  K. Mahaffey,et al.  Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials , 2017, Diabetes, obesity & metabolism.

[27]  D. V. van Raalte,et al.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. , 2017, Journal of the American Society of Nephrology : JASN.

[28]  A. Webster,et al.  Chronic Kidney Disease , 2017, The Lancet.

[29]  K. Tuttle.  Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney , 2016, Diabetes.

[30]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[31]  Y. Chang,et al.  Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury , 2016, PloS one.

[32]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[33]  K. Broglio,et al.  Interpretation of Clinical Trials That Stopped Early. , 2016, JAMA.

[34]  Merlin C. Thomas,et al.  Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease , 2016, Nature Reviews Nephrology.

[35]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[36]  F. Palm,et al.  Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. , 2015, American journal of physiology. Renal physiology.

[37]  A. Garg,et al.  Worldwide access to treatment for end-stage kidney disease: a systematic review , 2015, The Lancet.

[38]  B. Kasiske,et al.  Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) , 2014, Kidney international.

[39]  J. Coresh,et al.  GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[41]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[42]  Mark Woodward,et al.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. , 2011, Kidney international.

[43]  D. Kent,et al.  Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[44]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[45]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[46]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[47]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[48]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[49]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.